In Brief: National Medical Care grand jury probe
This article was originally published in The Gray Sheet
National Medical Care grand jury probe: U.S. Attorney General for the District of New Jersey will not pursue prosecution of possible criminal law violations regarding National Medical Care's efforts to convince FDA to lift a 1991 import ban of dialysis devices from the firm's Dublin, Ireland facility, the W.R. Grace unit announces. In February, the company received word that the New Jersey grand jury, which continues to investigate NMC's sale of allegedly defective products and handling of customer complaints, was considering action against NMC for violating federal rules prohibiting firms from making false submissions to the government ("The Gray Sheet" Feb. 19, I&W-14). The firm also is the target of a Virginia grand jury involving contractual relationships between NMC subsidiaries and service providers and an HHS probe regarding possible reimbursement violations...
You may also be interested in...
The C-suite leaders schemed to falsely record shipments of unwanted products to distributors as sales so the company could meet revenue projections, the government charged.
Gallium has been approved as a diagnostic agent by the US agency to help early detection of prostate cancer spread in patients who qualify for treatment with surgery or radiation therapy.
A joint report by the US Government Accountability Office and the National Academy of Sciences slams the FDA for dawdling on final software as a medical device rules.